1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Straumann Holding AG
  6. News
  7. Summary
    STMN   CH1175448666

STRAUMANN HOLDING AG

(STMN)
  Report
Real-time Estimate Cboe Europe  -  05/24 11:02:30 am EDT
113.48 CHF   -2.18%
05/20GLOBAL MARKETS LIVE : Take-Two, ASML, Spirit Airlines, Applied Materials, Foot Locker...
05/20Straumann to Acquire German Orthodontics Company PlusDental for $139 Million
MT
05/20STRAUMANN : to acquire PlusDental, a doctor-led clear-aligner treatment solutions provider in Europe
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Straumann invests in RODO Medical

08/13/2014 | 01:35am EDT

Straumann invests in RODO Medical

  • Straumann purchases approximately 12% of RODO Medical's shares for an undisclosed sum.
  • RODO Medical's highly innovative Smileloc™ System could have an important impact on implant prosthetic design, replacing cement and screws in implant restorations.

Basel/Sunnyvale, 13 August 2014: Straumann, a global leader in replacement, restorative and regenerative dentistry, and RODO Medical, Inc., a privately-held company developing innovative devices in dental implant restorations, have signed an agreement under which Straumann has acquired approximately 12% of RODO Medical's shares for an undisclosed sum.

The innovative Smileloc™ System

At the heart of the RODO Medical's Smileloc™ System is a retention mechanism utilizing shape memory properties of 'nitinol', a nickel-titanium alloy, which has been safely used for decades in stents and other medical devices, including orthodontic archwire and edotontic files. With Smileloc™, the crown or denture (prosthesis), can simply be fixed to the implant abutment without the need for cement or retaining screws. The Smileloc™ System eliminates disadvantages associated with cement and screws, and significantly simplifies the existing implant restoration process by allowing quick and easy removal of the prosthesis. This in turn can dramatically cut procedure time and cost without sacrificing esthetics. For more information, please visit www.rodomedical.com.

Straumann's CEO Marco Gadola commented: "Smileloc is an innovative concept designed to address a significant need. The first clinical results are promising and I agree with the developers that, when it becomes commercially available, it might substitute some of the current fixture technology. RODO Medical's entrepreneurial and scientific approach to innovation makes them an attractive partner for Straumann and we are excited about working together with them to change paradigms in dentistry".

RODO Medical's CEO Young Seo commented: "We are very excited about Straumann's investment in the company. Straumann is the global market leader in the dental implant industry and highly respected for its reliable products and responsible innovations".

About RODO Medical

RODO Medical is an innovative medical device company dedicated to improving the quality of life of patients and dentists. The company was founded in 2009 and is located in Sunnyvale, California. RODO Medical has developed novel retention devices in implant dentistry. The Smileloc™ System is used in permanent fixed restorations with dental implants and the Smileclip™ System is used in removable dentures with dental implants. The Smileloc™ System is not yet cleared by the FDA for marketing in the US, but has marketing clearance in Europe (CE Mark).

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2200 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners.




Provider
Channel
Contact
Tensid Ltd., Switzerland
www.tensid.ch


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50
All news about STRAUMANN HOLDING AG
05/20GLOBAL MARKETS LIVE : Take-Two, ASML, Spirit Airlines, Applied Materials, Foot Locker...
05/20Straumann to Acquire German Orthodontics Company PlusDental for $139 Million
MT
05/20STRAUMANN : to acquire PlusDental, a doctor-led clear-aligner treatment solutions provider..
PU
05/20Straumann Holding AG signed an agreement to acquire Sunshine Smile GmbH for CHF 135 mil..
CI
05/18Switzerland's Ypsomed To Appoint New Chairman In June
MT
05/02Mirabaud Securities Lifts Price Target on Straumann, Maintains Buy Recommendation
MT
05/02Mirabaud Securities Lifts Price Target on Straumann, Maintains Buy Recommendation
MT
04/28TRANSCRIPT : Straumann Holding AG, Q1 2022 Sales/ Trading Statement Call, Apr 28, 2022
CI
04/28Straumann's Q1 Revenue Grows 25% On Higher Patients Flow
MT
04/28STRAUMANN : reports very strong first quarter
PU
More news
Analyst Recommendations on STRAUMANN HOLDING AG
More recommendations
Financials
Sales 2022 2 324 M 2 406 M 2 406 M
Net income 2022 485 M 502 M 502 M
Net cash 2022 401 M 415 M 415 M
P/E ratio 2022 37,6x
Yield 2022 0,72%
Capitalization 18 490 M 19 145 M 19 145 M
EV / Sales 2022 7,78x
EV / Sales 2023 6,72x
Nbr of Employees 8 873
Free-Float 66,4%
Chart STRAUMANN HOLDING AG
Duration : Period :
Straumann Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends STRAUMANN HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 116,00 CHF
Average target price 170,46 CHF
Spread / Average Target 47,0%
EPS Revisions
Managers and Directors
Guillaume Daniellot Chief Executive Officer
Peter Hackel Chief Financial Officer
Gilbert Achermann Chief Executive Officer & Director
Christian Ullrich Group Chief Information Officer
Mark D. Johnson Head-Operations, Regulatory & Quality Affairs
Sector and Competitors
1st jan.Capi. (M$)
STRAUMANN HOLDING AG-40.11%19 145
SONOVA HOLDING AG-9.06%20 582
COCHLEAR LIMITED1.49%10 255
DEMANT A/S-14.53%9 060
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.-8.01%3 058
ANGELALIGN TECHNOLOGY INC.-52.13%2 741